T. Rowe Price Investment Management Inc. Lowers Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

T. Rowe Price Investment Management Inc. lessened its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,697,498 shares of the biopharmaceutical company's stock after selling 37,024 shares during the period. T. Rowe Price Investment Management Inc. owned about 2.56% of Celldex Therapeutics worth $42,896,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of CLDX. EverSource Wealth Advisors LLC boosted its stake in Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 878 shares in the last quarter. Headlands Technologies LLC acquired a new position in Celldex Therapeutics during the fourth quarter worth $81,000. KBC Group NV boosted its holdings in Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 1,647 shares in the last quarter. AlphaQuest LLC grew its holdings in Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after purchasing an additional 2,705 shares during the last quarter. Finally, Aristides Capital LLC acquired a new stake in shares of Celldex Therapeutics in the fourth quarter valued at approximately $202,000.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CLDX shares. Morgan Stanley started coverage on Celldex Therapeutics in a report on Thursday, March 20th. They set an "overweight" rating and a $46.00 target price for the company. The Goldman Sachs Group decreased their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Canaccord Genuity Group assumed coverage on Celldex Therapeutics in a report on Monday. They set a "buy" rating and a $64.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Friday, February 28th. Finally, UBS Group started coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They issued a "buy" rating and a $44.00 price objective on the stock. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $55.30.

Celldex Therapeutics Stock Up 0.2 %

Celldex Therapeutics stock traded up $0.05 during midday trading on Friday, hitting $20.76. 240,517 shares of the stock were exchanged, compared to its average volume of 881,286. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -8.07 and a beta of 1.59. The business's 50-day moving average price is $19.10 and its 200-day moving average price is $23.27. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The firm had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. On average, sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.